Drug
Samidorphan clinical trials
- studies test it
- 18
- open now
- 1
- in phase 3
- 6
- first study started
- 2008
Keep track of what changes. Save the samidorphan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
18 studies that test it; most in 2016 (5)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 2 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 4
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 1
Alkermes, Inc. (17) · National Institute on Drug Abuse (NIDA) (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses samidorphan is read from its arms, and is right about nine times in ten.
Testing it · 18
- Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsEnrolling by invitationPhase 3Alkermes, Inc.NCT04987229Written as OLZ/SAM
- Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831CompletedPhase 3Alkermes, Inc.NCT03201757Written as ALKS 3831
- Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I DisorderCompletedPhase 1Alkermes, Inc.NCT04987658Written as OLZ/SAM
- Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I DisorderCompletedPhase 3Alkermes, Inc.NCT03187769Written as ALKS 3831
- A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use DisorderCompletedPhase 2Alkermes, Inc.NCT02161718Written as Samidorphan + olanzapine (ALKS 3831)
- A Study of ALKS 3831 in Adults With SchizophreniaCompletedPhase 2Alkermes, Inc.NCT01903837Written as Samidorphan (Low Dose)
- A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With SchizophreniaCompletedPhase 3Alkermes, Inc.NCT02873208Written as ALKS 3831
- A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)CompletedPhase 3Alkermes, Inc.NCT02694328Written as ALKS 3831
- A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With SchizophreniaCompletedPhase 3Alkermes, Inc.NCT02669758Written as ALKS 3831
- An Insulin Sensitivity Study in Healthy SubjectsCompletedPhase 1Alkermes, Inc.NCT02922426Written as ALKS 3831
- Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy AdultsCompletedPhase 1National Institute on Drug Abuse (NIDA)NCT01046539Written as RDC-0313 + Buprenorphine
- A Phase 1 Safety Study in Adults With SchizophreniaCompletedPhase 1Alkermes, Inc.NCT02804568Written as ALKS 3831
- A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male VolunteersCompletedPhase 1Alkermes, Inc.NCT02504463Written as Samidorphan IV
- A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid UsersCompletedPhase 1Alkermes, Inc.NCT02218021Written as Samidorphan
- ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With CocaineCompletedPhase 1Alkermes, Inc.NCT01366001Written as ALKS 33-BUP
- ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating DisorderCompletedPhase 2Alkermes, Inc.NCT01098435Written as RDC-0313 (ALKS 33)
- ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol DependenceCompletedPhase 2Alkermes, Inc.NCT00981617Written as ALKS33 (RDC-0313) (1 mg)
- ALK33-001: A Study of RDC-0313 Administered to Healthy AdultsCompletedPhase 1Alkermes, Inc.NCT00800319Written as RDC-0313
Codes
What other systems call samidorphan · ClinicalTrials.gg INT000423
- MeSH (NLM) C000606131samidorphanOne source NLM
- UNII (FDA) 7W2581Z5L8SAMIDORPHANConfirmed FDA, NLM, Wikidata
- RxNorm 2559612One source FDA
- Wikidata Q7409428samidorphanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152293SamidorphanOne source FDA
- DrugBank DB12543One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000606131 | samidorphan | One source NLM |
| UNII (FDA) | 7W2581Z5L8 | SAMIDORPHAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2559612 | — | One source FDA |
| Wikidata | Q7409428 | samidorphan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152293 | Samidorphan | One source FDA |
| DrugBank | DB12543 | — | One source Wikidata |
Also registered as samidorphan l-malate (UNII 0AJQ5N56E0 · RxNorm 2570387).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.